Published by IQ4I on 31st July 2018 | Ref: 1005282 | This Report Is In Stock
Structural heart devices has emerged as a new focus area of medical device manufacturers as the population of most developed and developing countries continue to become older and risk of cardiovascular diseases increase with aging. The cardiovascular diseases which also include structural heart diseases have become leading cause of death. It is projected that, with newfound prosperity due to globalization and industrialization has led to changing lifestyle leading to increasing risk of younger people developing cardiovascular diseases. The increased interest has led to development of new technologies and devices that are less invasive and address the need of treatment of patients who are considered too weak to withstand the trauma of an open heart surgery.
According to IQ4I Analysis, Structural heart device market is expected to grow at double digit CAGR to reach ,671.0 million by 2024. The structural heart device market is classified based on product, product type and geography. The Structural heart devices market in this report is segmented by Product, Product type and Geography. Structural heart devices by product are segmented into Repair devices and Replacement devices. Repair devices by product type is segmented into Surgical Heart Repair (Annuloplasty) and Transcatheter heart repair devices. Transcatheter heart repair devices are further classified as Valvuloplasty, Occluders, Transcatheter Mitral Valve Repair and Others (Chordal replacement in mitral valve repair, Transcatheter tricuspid valve repair and Ventricular remodelling). Replacement devices by product type are segmented into Surgical Valve Replacement and Transcatheter Valve Replacement. Surgical valve replacement devices are further sub-segmented into Mechanical valves and Tissue valves. Transcatheter Valve Replacement devices are sub-segmented into Transcatheter aortic valve replacement (TAVR), Transcatheter Mitral valve replacement (TMVR), Transcatheter pulmonary valve replacement (TPVR).
The structural heart devices global market is segmented into repair and replacement devices based on the products. The replacement devices segment held the largest market revenue in 2017 and expected to grow at double digit CAGR from 2017 to 2024. In structural heart repair devices segment, transcatheter repair device held the largest share in 2017 and is projected to grow at a strong CAGR to reach ,165.7 million by 2024. Among transcatheter repair devices, Transcatheter mitral valve repair device held the largest share in 2017 and is projected to grow at high double digit CAGR from 2017 to 2024. The Structural heart Replacement segment is dominated by Transcatheter valve replacement in 2017 and expected to grow at a strong CAGR to reach ,232.0 million by 2024. Among the Surgical valve replacement devices, Tissue valves held the largest share of 85.3% in 2017 and are expected to grow at low single digit CAGR from 2017 to 2024. Among the Transcatheter valve replacement devices, Transcatheter Aortic Valve Replacement (TAVR) devices held the largest share in 2017 and Transcatheter Mitral Valve Replacement (TMVR) devices is expected to grow at high double digit CAGR from 2017 to 2024.
The structural heart devices market by geography is divided into North America (U.S., Others), Europe (Germany, Italy, France, Others), Asia-pacific (Japan, China, Korea, Others) and Rest of the World (Brazil, Rest of Latin America, Middle East and Others).
North America region commanded the largest revenue in 2017 due to high prevalence of cardiovascular disease such as heart failure, cardiogenic shock, dilated cardiomyopathy, ventricular insufficiency; Valvular heart disease, congenital heart diseases and growth in aging population and favorable reimbursement coverage led the market growth in this region. However, Asia-Pacific is expected to grow at double digit CAGR during the forecasting period owing to the rapidly increasing aging population with high prevalence of cardiovascular diseases, improving healthcare infrastructure and rise in healthcare spending in the emerging countries, such as India and China.
Some of the major players in structural heart devices market include Abbott laboratories (U.S.), Medtronic (Ireland), Boston Scientific (U.S.), Edward Lifesciences (U.S.), LivaNova (U.K.), Lepu Medicals (China), JenaValve Technologies GmbH (Germany), Braile biomedia (Brazil), Cryolife (U.S.), Labcore Laboratories ltd (Brazil).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
• Rest of the World (RoW)
o Rest of Latin America
o Middle East & Others
1 EXECUTIVE SUMMARY 22
2 INTRODUCTION 27
2.1 KEY TAKEAWAYS 27
2.2 SCOPE OF THE REPORT 28
2.3 REPORT DESCRIPTION 28
2.4 MARKETS COVERED 31
2.5 STAKEHOLDERS 32
2.6 RESEARCH METHODOLOGY 32
3 MARKET ANALYSIS 41
3.1 INTRODUCTION 41
3.2 MARKET SEGMENTATION 42
3.3 FACTORS INFLUENCING MARKET 44
3.4 REGULATORY AFFAIRS 51
3.5 REIMBURSEMENT SCENARIO 58
3.6 PATENT TRENDS 65
3.7 TECHNOLOGICAL ADVANCEMENTS 66
3.8 CLINICAL TRIALS 70
3.9 PORTER’S FIVE FORCE ANALYSIS 77
3.10 SUPPLY CHAIN ANALYSIS 80
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 83
3.12 STRUCTURAL HEART DISEASES U.S. MARKET PENETRATION, PREVALENCE, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED 96
3.13 STRUCTURAL HEART DEVICES NUMBER OF UNITS BY REGION 98
3.14 STRUCTURAL HEART DEVICES COMPANY COMPARISON TABLE BY PRODUCTS 104
4 STRUCTURAL HEART DEVICES GLOBAL MARKET, BY PRODUCT 127
4.1 INTRODUCTION 127
4.2 STRUCTURAL HEART REPAIR DEVICES 132
4.3 STRUCTURAL HEART VALVE REPLACEMENT DEVICES 157
5 REGIONAL ANALYSIS 186
5.1 INTRODUCTION 186
5.2 NORTH AMERICA 189
5.3 EUROPE 206
5.4 APAC 227
5.5 ROW 247
6 COMPETITIVE LANDSCAPE 265
6.1 INTRODUCTION 265
6.2 APPROVALS 266
6.3 ACQUISITIONS 272
6.4 NEW PRODUCT LAUNCH 274
6.5 AGREEMENTS 275
6.6 OTHER DEVELOPMENTS 275
7 MAJOR COMPANIES 277
7.1 ABBOTT LABORATORIES 277
7.2 BOSTON SCIENTIFIC CORPOARTION 284
7.3 BRAILE BIOMEDICA 292
7.4 CRYOLIFE, INC. 295
7.5 EDWARDS LIFESCIENCES CORP. 303
7.6 JENAVALVE TECHNOLOGY 311
7.7 LABCOR LABORATORIOS LTDA. 313
7.8 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 316
7.9 LIVANOVA PLC (SORIN GROUP) 319
7.10 MEDTRONIC, PLC 327
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Buy now using our secure payment system.